HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has ...

The Trump administration is impeding the National Institutes of Health-backed science that enabled treatment of ...

TC BioPharm (TCBP) has signed a non-binding letter of intent (LoI) to acquire an ophthalmic pharmaceutical company focused on ...

MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.

The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.

At a hearing, Dr. Marty Makary, the nominee for F.D.A. commissioner, fielded questions focused on whether he would review or ...

The Trump administration is impeding the National Institutes of Health-backed science that enabled treatment of ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

A novel stem cell therapy demonstrated potential in restoring the corneal surface in patients with blinding corneal injuries.

We talked to pilots, psychiatrists, flight attendants, and even the Flight Safety Foundation to get you the scoop on how to ...